The global Escherichia Coli Strain Market is estimated to be valued at US$ 1.97 Bn in 2023 and is expected to exhibit a CAGR of 6.9% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Escherichia Coli (E.Coli) is one of the most widely used expression systems for industrial and research applications. E.coli strain helps in the production of pharmaceutical proteins at lower costs which is driving its demand from biopharma companies. E.Coli expresses proteins that can then be extracted and purified by various downstream processes. It has the ability to synthesize complex proteins with human-like posttranslational modifications which is a key advantage. E.Coli strains are used as a host for genetic manipulation and protein expression in research and commercial applications for developing functional foods and monoclonal antibody therapies.
Market key trends:
One of the key trends in the market is the increasing demand for new expression systems to enhance functional food production. Research institutes are focusing on developing novel E.Coli strains that can express human gut bacterial genes. This enables the production of next-gen functional foods with prebiotic and probiotic properties. Another trend is the customized development of E.Coli strains for monoclonal antibody therapies. Companies are engineering strains for high-yield and large-scale production of therapeutic antibodies using advanced gene-editing technologies like CRISPR. This is helping reduce the cost of biologic drugs. Advancements in microbial strain engineering technologies will continue to expand the application scope of E.Coli in the coming years.
Porter’s Analysis
Threat of new entrants: The threat of new entrants is moderate in the Escherichia coli strain market as high capital investments are required to set up research and production facilities for Escherichia coli strains. Additionally, existing players have significant brand awareness and control a major market share.
Bargaining power of buyers: The bargaining power of buyers is moderate. While large diagnostic companies and research organizations have significant purchasing power, the specialized nature of Escherichia coli strains limits substitutes.
Bargaining power of suppliers: The bargaining power of suppliers is low due to the availability of a large number of suppliers. Additionally, raw materials used in Escherichia coli strain production such as media and reagents are widely available.
Threat of new substitutes: The threat of substitutes is low as Escherichia coli is irreplaceable for various metabolic engineering and synthetic biology applications.
Competitive rivalry: The Escherichia coli strain market witnesses high competitive rivalry between major players.
Key Takeaways
Global Escherichia Coli Strain Market Demand is expected to witness high growth, exhibiting CAGR of 6.9% over the forecast period, due to increasing investments in synthetic biology and metabolic engineering projects around the world.
Regional analysis
North America is expected to dominate the global Escherichia coli strain market during the forecast period. This is attributed to significant research funding and presence of leading players in the region. Asia Pacific is anticipated to exhibit the fastest growth rate owing to rising biotechnology industry and increasing R&D expenditures in countries such as China and India.
Key players analysis
Key players operating in the Escherichia coli strain market include Thermo Fisher Scientific Inc., Merck KGaA, Novozymes A/S, QIAGEN N.V., Promega Corporation, Agilent Technologies, Inc., New England Biolabs, Inc., Takara Bio Inc., Bio-Rad Laboratories, Inc., and GenScript Biotech Corporation. Thermo Fisher Scientific Inc. and Merck KGaA collectively account for a major market share.
Read More- https://www.ukwebwire.com/escherichia-coli-strain-market-growth-anlaysis-and-outlook/
